Palvella Therapeutics Q3 2026 Earnings Date & Estimates

Palvella Therapeutics (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement. Palvella has also evaluated its QTORIN platform in other rare dermatologic conditions, including manifestations associated with tuberous sclerosis complex.

The company conducts its research and development activities primarily in the United States and works with clinicians and patient communities focused on rare diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania, and its programs remain centered on advancing specialized treatments through clinical development and regulatory review.